Developing a new cancer immunotherapy, SurVaxM from bench to bedside

MimiVax, Inc. is developing immunotherapeutic vaccines and targeted therapies for treating cancers and preventing recurrence. The company’s lead agent, SurVaxM, targets survivin, a cell-survival protein expressed in cancer cells.


​https://www.nature.com/articles/d43747-024-00019-5